Attenuation of infectious bronchitis virus variant GA-13
AssigneeUniversity of Georgia Research Foundation, Inc.
InventorHolly S. Sellers
Life of this patent
Estimating the term…
Abstract
The present invention provides the isolation and characterization of a new infectious bronchitis virus (IBV) variant, the IBV GA-13 variant, and the production of attenuated isolates thereof, including, but not limited to, the attenuated IBV GA13 isolate 103505 Kd E86, and the use of such IBV isolates in materials and methods for combating infectious bronchitis virus in poultry and reducing the economic impact that infectious bronchitis disease has on poultry production.
Claims19
An attenuated infectious bronchitis virus (IBV) GA13 isolate, wherein the attenuated IBV GA13 isolate comprises GA13 103505 Kd E86 deposited under ATCC Accession Number PTA-124038.
An attenuated infectious bronchitis virus (IBV) GA13 isolate, the attenuated IBV GA13 isolate comprising an S1 glycoprotein subunit comprising an amino acid sequence comprising at least about 95% sequence identity to SEQ ID NO:
- 4, wherein SEQ ID NO:
- 4 comprises the amino acid sequence of the S1 glycoprotein subunit of the attenuated IBV GA13 isolate GA13 103505 Kd E86 deposited under ATCC Accession Number PTA-124308.
An attenuated infectious bronchitis virus (IBV) GA13 isolate, the attenuated IBV GA13 isolate comprising an S1 glycoprotein subunit encoded by a nucleotide sequence comprising at least about 95% sequence identity to SEQ ID NO:
- 3, wherein SEQ ID NO:
- 3 comprises the nucleotide sequence encoding the S1 glycoprotein subunit of the attenuated IBV GA13 isolate GA13 103505 Kd E86 deposited under ATCC Accession Number PTA-124308.
Dependencies are inferred from the claim text.